NICE 2026 Updates Type 2 Diabetes Care: Cardiovascular Focus, Early SGLT-2 Use Takes Forefront

The most recent version of NG28, the National Institute for Health and Care Excellence's (NICE) guidelines for managing type 2 diabetes in adults, has been released on February 18, 2026.

The revised guidelines represent a significant shift towards cardio-renal protective treatments, and improved patient-centric approach. Here are some of important updates

Early Combination Therapy

It is now advised to initiate combination therapy early. NICE now suggests that persons with type 2 diabetes who do not have any pertinent comorbidities be treated with modified-release metformin and an SGLT-2 inhibitor as their first-line of treatment.

This is an alteration from the previous gradual intensification strategy and is consistent with growing evidence that SGLT-2 inhibitors have positive effects on the kidneys and heart.

The same combined therapy modified-release metformin plus an SGLT-2 inhibitor is recommended for people with established heart failure. SGLT-2 inhibitor monotherapy should be recommended if metformin is contraindicated or not tolerated.

NICE recommends early combination therapy with metformin and SGLT-2 inhibitor in individuals with Atherosclerotic Cardiovascular Disease (ASCVD) for their cardiovascular, renal, and glycaemic benefits. A GLP-1 receptor agonist, up to 1 mg weekly may be considered for additional glycaemic control.

Increased Attention to Heart and Renal Risk

The 2026 update emphasizes the importance of evaluating renal and cardiovascular health prior to starting treatment. Clinical professionals are advised to assess frailty and adjust treatment, especially for individuals with comorbidities.

Crucially, GLP-1RA and SGLT-2 inhibitors are advised for both glycaemic control and their proven cardioprotective and reno-protective benefits.

Prioritization of GLP-1 Receptor Agonists and SGLT-2 Inhibitors over DPP-4 inhibitors

SGLT-2 inhibitors and GLP-1RA have gained priority in therapy, according to the most recent 2026 updates, which represents a transforming change.

Beyond a glucose-centric approach, NICE now gives these medicines priority for their proven cardiovascular and renal protective advantages in addition to their ability to lower HbA1c.

In addition to improving glycaemic management, SGLT-2 inhibitors have been shown to minimize cardiovascular risk, halt the progression of chronic renal disease, reduce heart failure hospitalization, and help with mild weight reduction.

Interestingly, SGLT-2 inhibitors are now advised as part of first-line therapy in combination with modified-release metformin for the majority of patient groups, including those with early-onset type 2 diabetes. Their prioritization in chronic kidney disease in particular is based on solid outcome data showing renal preservation even at lower eGFR levels. It further highlights the importance of GLP-1RA, due to the combined cardiovascular, renal, and glycaemic advantages.

On the other hand, DPP-4 inhibitors, which were previously thought to be broadly comparable second-line treatments, have been moved down the therapy hierarchy.

A Renewed Focus on Collaborative Decision-making & Discuss “Sick Day” Rules

When selecting a treatment, clinicians are encouraged to talk about the advantages, hazards, weight impacts, cardiovascular outcomes, and financial factors.

Each patient's personalized plan must include explicit "sick day rules," such as instructions on how to modify medications during acute sickness, particularly for metformin, insulin, and SGLT-2 inhibitors. The first-line use of SGLT-2 inhibitors to be discontinued to reduce the risk of euglycaemic diabetic ketoacidosis, an uncommon but dangerous complication.

NICE further limits the use of sulfonylureas due to hypoglycaemia and weight gain related concerns. It also suggests that its use must be reserved mainly for cost-constrained patients.

The overall NICE update indicates a paradigm shift in the management of diabetes, giving priority to cardiovascular risk reduction, early combination therapy, equitable access, and truly patient centric care.

Reference: NICE Guidelines,2026